Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Cartesian Therapeutics

Cartesian Therapeutics (NASDAQ: RNAC) insider transactions

In the twelve months to 10 November 2026, executives and directors of Cartesian Therapeutics reported 3 open-market sales of 37,930 shares ($258,683) and 1 open-market purchase of 30,000 shares ($205,800), by 4 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Cartesian Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
2 April 2026Kalayoglu Murat—Option exercise+758,001—5,313,261Form 4
2 April 2026Hoge Elizabeth—Option exercise+758,001—5,313,261Form 4
13 March 2026Singer MichaelDirectorGift−6,555—49,578Form 4
6 January 2026Davis BlaineChief Financial OfficerOpen-market sale−10,591$6.82121,220Form 4
6 January 2026Miljkovic MilosChief Medical OfficerOpen-market sale−3,573$6.8258,820Form 4
6 January 2026Brunn CarstenPresident and CEOOpen-market sale−23,766$6.82323,530Form 4
2 January 2026Kalayoglu MuratDirectorGrant or award+2,600—511,577Form 4
2 January 2026Springer Timothy ADirectorGrant or award+2,600—8,646,285Form 4
2 January 2026Singer MichaelDirectorGrant or award+2,600—56,133Form 4
2 January 2026English EmilyChief Operations OfficerGrant or award+24,000—94,226Form 4
2 January 2026Barabe Timothy CDirectorGrant or award+2,600—56,966Form 4
2 January 2026Davis BlaineChief Financial OfficerGrant or award+37,000—131,811Form 4
2 January 2026Seymour June AnnChief Accounting OfficerGrant or award+6,500—6,500Form 4
2 January 2026Zenner Patrick JDirectorGrant or award+2,600—12,974Form 4
2 January 2026Miljkovic MilosChief Medical OfficerGrant or award+27,000—62,393Form 4
2 January 2026Malik KemalDirectorGrant or award+2,600—11,133Form 4
2 January 2026Brunn CarstenPresident and CEOGrant or award+143,200—347,296Form 4
2 January 2026DeSilva Nishan MDirectorGrant or award+2,600—11,366Form 4
30 December 2025English EmilyChief Operations OfficerOption exercise+7,500$3.3070,226Form 4
16 December 2025Bot Adrian IonDirectorGrant or award+5,800—5,800Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Cartesian Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.